Boehringer In­gel­heim inks deal for tar­get­ed can­cer an­ti­bod­ies from Sin­ga­pore re­search org

As Boehringer In­gel­heim looks to build out its ef­forts in on­col­o­gy, its lat­est deal will turn to­ward Sin­ga­pore.

The Ger­man phar­ma an­nounced Thurs­day that it has signed a glob­al li­cens­ing agree­ment with the Sin­ga­pore-based Agency for Sci­ence, Tech­nol­o­gy and Re­search (A*STAR). While spe­cif­ic fi­nan­cial break­down was not dis­closed, Boehringer will pay more than €100 mil­lion ($107 mil­lion) in up­front cash and mile­stones, as well as suc­cess-based de­vel­op­ment and com­mer­cial­iza­tion tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER